Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
LONDON--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT), the global leader in B2B technology purchase intent data and services, today announced the 2024 EMEA winners of the Archer Awards, the Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback